Xcout Intel
Orbus Therapeutics, Inc.
Orbus Therapeutics, Inc. is a pharmaceutical company headquartered in Menlo Park, California, dedicated to developing treatments for rare forms of cancer, including clinical trials for brain tumors.
Subscribe to see Orbus Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Orbus Therapeutics, Inc. at a glance
Orbus Therapeutics, Inc. is a biotechnology company headquartered in United States, founded in 2012. Its most recent funding round raised $10M in July 2020. Xcout tracks 8 named people at Orbus Therapeutics, Inc., including Jackie Walling (CHIEF MEDICAL OFFICER (CONSULTANT)).
Orbus Therapeutics, Inc. leadership
- Jackie WallingCHIEF MEDICAL OFFICER (CONSULTANT)
- Noymi Yam, PhDVICE PRESIDENT, CHIEF SCIENTIFIC OFFICER
- Jason LevinFounder, Director and chief executive officer
- Jennifer EkelundHEAD, REGULATORY AFFAIRS AND QUALITY ASSURANCE
- Alex ZissonManaging Director, H.I.G. HealthBridge Partners
- Patrick EnrightManaging Director, Longitude Capital
2 more named people on record for Orbus Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Orbus Therapeutics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $10M | — | |
| Series A | $10M | 4 named | |
| SEC Form D filing | $18.5M | — | |
| SEC Form D filing | $18M | — | |
| Series A | $32.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Orbus Therapeutics, Inc. competitors
A few of Orbus Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Ayala Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Monmouth Junction, New Jersey. The company focuses on developing targeted therapeutics for rare tumors and aggressive cancers. It engages in clinical research and asset management within the biotechnology and pharmaceutical sector.
Ambros Therapeutics is a clinical-stage biotechnology company headquartered in Irvine, California, focused on the development of innovative therapeutics.
Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted cancer therapies, with a focus on diseases affecting children and adults. Its lead product, tovorafenib (Ojemda), is an FDA-approved treatment for pediatric patients with relapsed or refractory low-grade glioma harboring qualifying BRAF alterations.
Get Orbus Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Orbus Therapeutics, Inc. in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access